This is what I think has happened here...
If you are a trader...$103+
If an investor, make popcorn and watch the games being played by the FUNDS
Maybe $103 today..?
good news is the lower trading price is higher than the previous one...the $5 trading range is now $3,,,$2...etc
$103+ is short term resistance by day traders
101.66 Up 0.70 (0.69%) 8:58AM EDT - Nasdaq Real Time Price
$103+ is short term resistance...four times in the past few weeks
it was posted Friday afternoon that AAPL would "gap at the open".
have a nice day
I like to close out the sale of any option once it falls 50% then reload selling another for the original 100% sales price...Of course, this results in taxes
this is tax deferred, non interest cash.
My suggestion on July 30, was to sell the Jan 2016 $90 puts for $10
If the stock runs...the put premium falls = profit
if the stock falls below $87.50 this person may have to buy the stock at a 12% discount to market now
Maybe someone who had sold the Jan 2016 calls for $9+ bought the Oct $55 calls for .70.
THey have upside action and still $8.30 cash per share in their pocket
On September 17, 2014, CASI Pharmaceuticals, Inc., a Delaware corporation ("CASI" or the "Company"), entered into investment agreements (the "Investment Agreements") and issued an aggregate of 5,405,382 shares of its Common Stock to Spectrum Pharmaceuticals, Inc., a Delaware corporation and its affiliate, Spectrum Pharmaceuticals Cayman, L.P., an Exempted Limited Partnership organized under the laws of the Cayman Islands (together "Spectrum"). In consideration for the shares, CASI received perpetual (subject to customary provisions on termination) exclusive licenses to develop and commercialize Captisol-Enabled� (propylene glycol-free) melphalan (CE melphalan) and ZEVALIN� (ibritumomab tiuxetan) in China, including Taiwan, Hong Kong and Macau ("Greater China"). The shares issued at the closing represent approximately 19.99% percent of CASI's outstanding shares prior to the transaction. CASI also delivered to Talon Therapeutics, Inc., another affiliate of Spectrum, a $1.5 million promissory note, payable 18 months after the closing of the transaction, for exclusive Greater China rights to an additional commercial oncology drug, MARQIBO� (vinCRIStine sulfate LIPOSOME injection). The note is secured by the license granted by Spectrum to CASI for MARQIBO. A copy of the promissory note is filed as Exhibit 4.2 to this Current Report on Form 8-K and incorporated herein by reference.
if pit premium drops on $9- puts down to $5 from $10 you can close these out then sell another put for $10...putting then $15 in your pocket
options "usually" allow am investor a chance to correct a mistake.
My mistake was not a mistake...This year, it was my strategy to make all companies grow into valuations beforehand
typo...Buy Jan 2015 $2.50 calls for $2.15 then sell the $5 calls for $1.05